Biolink Group AS
In the early eighties, scientific researchers at the University of Bergen, Norway, established a project mapping specific strong bioactive natural plant substances. After intensive research and bio-prospecting during the eighties and nineties, covering thousands of flavonoids, the researchers concluded that anthocyanins were superior. These research results were the basement for the foundation of Biolink Group AS late 1998.
In 1999 scientists in Biolink Group’s laboratories in Sandnes established a follow-up scientific research program to create a genuine strong, health-promoting anthocyanin product. The goal was to make a prophylactic and therapeutic Nutraceutical, later named Medox®.
Anthocyanins are small, water-soluble molecules (~500g/mole) able to penetrate cell walls and the blood-brain barrier. They possess a vast number of potential biological and medical effects:
• ”Triggering” genes, enzymes, proteins and hormones
• Modulating the endocrine system (eNOS, iNOS, nNOS)
• Improving Endothelial function (FMD, sVCAM-1, NOS, NO-cGMP)
• Lowering Chronic Inflammation (NF-ĸB, TNFα, IL-n, IFNα, IFNg,- – – )
• Modulating/strengthening the immune system through GSH synergy
• Impeding growth and spread of cancer cells (Apopt., Matrix Metallo Proteinases (MMP), COX-2, NF-ĸB, VEGF, p38, p53, TNF-α, CETP, . . )
• Reducing risk of cardiovascular diseases (Improves cholesterol structure by modulating CETP mass and activity, increasing HDL and lowering LDL)
• Reducing rate of cognitive decline in older adults
• Regulating Lipogenesis, inhibiting Hepatic Steatosis and fighting diabetes 2
• Fighting viruses
Both Medox® and its main molecules, C 3G and D 3G have been subject to independent clinical studies, including human, randomized, double blind, placebo controlled studies at universities and university hospitals in Norway, EU, PR of China and USA since 2000.
Clinical studies substantiating sensational health-promoting effects of Medox® and the main catechol structured anthocyanin molecules provided by our laboratories have been published in different international nutrition- and medical journals such as:
• ”The Journal of Nutrition”, USA-2007, Chronic Inflammation
• ”The American Journal of Clinical Nutrition”, USA-2009, Vascular Diseases, Cholesterol structure improvement, CETP
• ”Clinical Chemistry”, USA-2011, Chronic Inflammation, Vascular Diseases
• ”Arteriosclerosis, Thrombosis and Vascular Biology”, USA-2007, Chronic Inflammation
• ”The Journal of Federation of American Societies for Experimental Biology”, USA-2004, Cancer
• ”The Journal of Lipid Research”, USA-2011, Diabetes
• “Molecular and Cellular Biochemistry”, USA-2011, Vascular Diseases
• ”Nutrition, Metabolism & Cardiovascular Diseases”, USA- 2012, Inflammation, cholesterol
• “Genes & Nutrition”, New York/Heidelberg 2012, Cardiovascular Diseases
One very interesting clinical study on Medox®: “Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transport protein (CETP) in dyslipidemic subjects” (Wenhua Ling et al; Sun Yat-sen University, Guangzhou, China; published in “The American Journal of Clinical Nutrition”, USA 2009) showed that Medox® modulating CETP lowered LDL and elevated HDL cholesterol.
At the same time a very interesting gene study was performed in NY. An Alzheimer’s study (n=500) showed that people with a “CETP gene” that elevated HDL and lowered LDL had 70 % less risk of developing Alzheimer’s; Dr Richard Lipton, Albert Einsteins college of medicine, Yeshiva University, New York, 2009).
And, furthermore supported by ”Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia”; Dr. Amy E. Sanders et al; JAMA”, USA.
This raised the question of whether there could be a connection between CETP modulation of anthocyanins and Alzheimer’s.
At the time being, Biolink Group together with dementia researchers in the Regional Resource Centre for Geriatric Medicine and Interaction (SESAM) at the University Hospital in Stavanger are starting clinical studies on anthocyanins (Medox®) and Alzheimer’s. The University Hospital in Bergen and Karolinska University Hospital in Stockholm will later be included in the project.
Only time will show if anthocyanins could be just as effective counteracting development of Alzheimer’s, as they are inhibiting Chronic Inflammation, CVD and Cancer.
As of today, Biolink Group with its R&D laboratories and manufacturing plant are supplying the Norwegian market with half a million boxes of Medox® on an annual basis.